The Chateaux Deer Valley is the host conference venue. We also have sleeping rooms at the Stein Eriksen Lodge Deer Valley. Sleeping rooms can be secured for The Chateaux and The Stein after completing the conference registration (following the prompts to the “Select Hotel” button). There are limited sleeping rooms available at both venues.
Alternately, please find some suggested hotels that are within a 15 minute drive from The Chateaux.
PLEASE NOTE: MASH-TAG has not secured special rates/room blocks at the alternate lodging options.
View the agenda for the planned presentations and events of MASH-TAG 2025.
View AgendaMASH-TAG is sponsored by Madrigal Pharmaceuticals and others.
See Our Sponsors
Vlad Ratziu
MD, PhD
Rohit Loomba
MD, MHSc
Mary E. Rinella
MD
Quentin Anstee, MD
Newcastle University
Newcastle-Upon-Tyne, United Kingdom
Samuel Klein, MD
Washington University School of Medicine
St. Louis, Missouri, USA
Philip Newsome, MBBS
University of Birmingham
Birmingham, United Kingdom
Mazen Noureddin, MD, MHSc
Houston Liver Institute, Medical Director
Los Angeles, California, USA
Brent Tetri, MD
Professor of Internal Medicine
Co-Director, Saint Louis University Liver Center
St. Louis, Missouri, USA
Manal Abdelmalek, MD
Mayo Clinic
Rochester, Minnesota, USA
We are pleased to announce that the 2026 MASH-TAG Conference, our 10th annual conference, will be held from Thursday, January 8 to Saturday, January 10, 2026, in Deer Valley / Park City, UT. The conference will be held in hybrid format, providing an effective, engaging, and safe opportunity to learn from leading researchers, participate in interactive discussions, and share insights with others on multiple topics related to advances in the diagnosis, management and therapeutic agent development for Metabolic Dysfunction-Associated Steatohepatitis (MASH) and liver fibrosis.
The primary objective of the MASH-TAG Conference is to meet the educational and networking needs of research and development stakeholders and healthcare professionals seeking to improve the lives of patients with MASH. This unique conference brings together clinicians, academia, and the pharmaceutical industry to discuss the identification of appropriate patient populations, trial designs, and therapeutic endpoints, as well as the potential benefits these agents can have on patients with MASH. We believe the success of this conference is accomplished by delivering a focused, scientific, forum that highlights the most clinically relevant advances in MASH, including future directions in diagnostic procedures and challenges in drug discovery and development for both MASH and liver fibrosis.
The Scientific Advisory Board Committee of MASH-TAG is an internationally renowned group of academic researchers who help provide comprehensive strategic planning and guidance for the educational program. These renowned experts assist in developing the educational content and serve as faculty at the conference. MASH-TAG 2026 will address the latest clinical trial results, design updates, new pharmacological updates, and the pharmacoeconomic benefits of future treatment to the healthcare system. In addition, the faculty will focus on epidemiology, comorbidities associated with these diseases, and the impact of MASH (natural history).
We will also honor the lasting legacy of the late Dr. Stephen A. Harrison, one of the founding figures of MASH-TAG, whose vision and contributions continue to inspire the conference.
All Copyright © Reserved by MASH-TAG
